Patients undergoing treatments in hospitals may develop some infections during their stay in the hospitals, which are known as hospital-acquired infections (HAI) or hospital infections. These infections transmit in healthcare settings such as nursing homes, rehabilitation centers, hospitals, dialysis centers, and outpatient surgery centers. Hospital-acquired infections are induced by viral, bacterial, and fungal pathogens.

1. Rising Occurrence of HAIs to Increase
Global Demand for Hospital Infection
Therapeutics Market, Reports TMR
Concerns over increasing incidence of hospital-acquired
diseases or nosocomial diseases have prompted healthcare
authorities and providers to focus more on the adoption of
hospital infection therapeutics as a safety measure.
A study by the World Health Organization (WHO) indicates that
out of every 100 hospitalized patients at a particular time, 7 in
developed and 10 in developing countries will get infected by at
least one hospital-acquired infection. As the geriatric and
neonatal population in the hospital settings is more susceptible
to acquiring these diseases, a rise in these demographics is
expected to give a significant push to the global hospital
infection therapeutics market.
Transparency Market Research (TMR) forecasts that the
aforementioned factors are expected to give an impetus to the
market. According to a report by TMR, the global hospital
infection therapeutics market stood at US$3.1 bn in 2013 and is
anticipated to rise to US$3.6 bn by 2020, expanding at a 3.1%
CAGR from 2014 to 2020.

2. How are government initiatives influencing the growth of the
global hospital infection therapeutics market?
The absence of regulatory bodies and efficacious control
programs is inhibiting the growth of the market in many parts of
the world. For instance, in Africa, several countries do not have
control authorities or efficient programs to control or prevent the
spread of hospital-acquired diseases.
Browse Full Research Report on Hospital Infection
Therapeutics Market:
http://www.transparencymarketresearch.com/hospital-infection-
therapeutics.html
In the U.S., the unwillingness or inability of government
agencies have caused failure in tracking the number of deaths
due to hospital-acquired diseases. These trends hinder the
widespread awareness about hospital-acquired diseases, thereby
restraining the global hospital infection therapeutics market.
On the other hand, the increasing infection control and hospital
surveillance programs in developed countries are leading to a
reduction in the cases of hospital-acquired infections. As a
result, the demand for hospital infection therapeutics is expected
to decrease.

3. Which trends are expected to influence the growth of the
global hospital infection therapeutics market in the near
future?
The global hospital infection therapeutics market is facing
considerable challenges due to increasing antimicrobial
resistance among certain strains of bacteria such as Methicillin-
Resistant Staphylococcus Aureus (MRSA), which has rendered
available drugs obsolete.
However, the presence of a huge scope for the development of
hospital infection therapeutics has resulted in an increasing
number of pipeline drug molecules for treating a range of multi-
drug resistant microbes. Additionally, some manufacturers and
researchers are developing vaccines to address the increasing
prevalence of hospital-acquired infections (HIS).
This trend is likely to augur well for the growth of the market in
the coming years. Moreover, the increasing demand for these
therapeutics from emerging nations is anticipated to present
immense growth opportunities to the manufacturers.
Which trends are positively influencing the growth of the
hospital infection therapeutics market in developed and
developing regions?

4. Geographically, North America dominated the market in terms
of revenue in 2013, followed by Europe. Factors such as the
rising number of multi-drug resistant microbial pathogens, high
ratio of hospitals per thousand of the population, high
prevalence of various hospital infections, and increasing demand
for advanced therapeutics, especially in the developed countries
of these regions, are fuelling the growth of the market.
In most of the low to medium income countries in Asia Pacific,
the demand for hospital infection therapeutics will increase due
to the presence of a large patient pool suffering from HIS, lack
of standard healthcare facilities, low social awareness, and
unfavorable environmental conditions.
In developing countries, the continuously improving healthcare
infrastructure coupled with increasing consumer purchasing
power is likely to boost the adoption of hospital infection
therapeutics. These factors, collectively, are estimated to
contribute to the significant growth of Asia Pacific as a regional
market for hospital infection therapeutics.

5. Browse Full Press Release on Hospital Infection
Therapeutics Market:
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Press Release

6. Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com